MDGL Madrigal Pharmaceuticals

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022.

The schedule for the press release and conference call/webcast is as follows:

• MAESTRO-NASH Press Release: December 19th, 2022 at 7:00 am EST
• MAESTRO-NAFLD-1 Conference Call:   December 19th, 2022 at 8:00 am EST
   

To access the live webcast of the call with slides please visit the Investors section of Madrigal’s website or click . To access the call by phone, please go to this link (), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. An archived webcast will be available on the Madrigal website after the event.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit .

Investor Contact

Alex Howarth, Madrigal Pharmaceuticals, Inc.,

Media Contact

Christopher Frates, Madrigal Pharmaceuticals, Inc.,



EN
18/12/2022

Underlying

MDGLMadrigal Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Madrigal Pharmaceuticals

 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual He...

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and may be accessed or by visiting Madrigal’s Investor Relations Events . A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopha...

February 24, 2026 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Fin...

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- M...

February 19, 2026 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on February 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in...

February 17, 2026 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agr...

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatmentMadrigal will develop next-generation siRNA therapies that silence genes implicated in MASH CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metaboli...

February 11, 2026 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on February 1, 2026 to 21 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch